NO914541L - Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner - Google Patents

Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner

Info

Publication number
NO914541L
NO914541L NO91914541A NO914541A NO914541L NO 914541 L NO914541 L NO 914541L NO 91914541 A NO91914541 A NO 91914541A NO 914541 A NO914541 A NO 914541A NO 914541 L NO914541 L NO 914541L
Authority
NO
Norway
Prior art keywords
muteins
muteines
necrose
factor
procedure
Prior art date
Application number
NO91914541A
Other languages
English (en)
Other versions
NO914541D0 (no
Inventor
Walter Fiers
Jan Tavernier
Xaveer Van Ostade
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO914541D0 publication Critical patent/NO914541D0/no
Publication of NO914541L publication Critical patent/NO914541L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Human tumor-nekrose-faktor-mutein eller et far-masoytisk akseptabelt salt derav særpreget ved at TN F sekvensen er endret ved delesjon, innsetning og/eller substitusjon av én eller flere aminosyrer, slik at muteinet viser en signifikant forskjell mellom sin bindingsaffinitet for den humane ptumor-nekrose-faktor-reseptor, DNA sekvenser som koder for slike muteiner, vektorer omfattende slike DNA sekvenser, vertsceller transformert med slike vektorer, samt en fremgangsmåte for fremstilling av slike muteiner og som anvender slike transformerte vertsceller og farmasøytiske blandinger inneholdende slike muteiner samt deres bruk for behandlingen av lidelser, slik som kreft.
NO91914541A 1990-11-21 1991-11-20 Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner NO914541L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90810901 1990-11-21

Publications (2)

Publication Number Publication Date
NO914541D0 NO914541D0 (no) 1991-11-20
NO914541L true NO914541L (no) 1992-05-22

Family

ID=8205969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914541A NO914541L (no) 1990-11-21 1991-11-20 Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner

Country Status (17)

Country Link
US (2) US5422104A (no)
EP (1) EP0486908A3 (no)
JP (1) JPH06256395A (no)
AR (1) AR245783A1 (no)
AU (1) AU655948B2 (no)
CA (1) CA2055168A1 (no)
FI (1) FI915379A7 (no)
HU (1) HUT62034A (no)
IE (1) IE914035A1 (no)
IL (1) IL100062A0 (no)
MC (1) MC2300A1 (no)
MX (1) MX9102110A (no)
NO (1) NO914541L (no)
NZ (1) NZ240595A (no)
PT (1) PT99560A (no)
UY (1) UY23327A1 (no)
ZA (1) ZA919035B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283533B6 (cs) * 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
BR0313033A (pt) * 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
ES2537738T3 (es) * 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
JP2007511507A (ja) * 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
EP1598075A1 (en) * 2004-05-21 2005-11-23 LEK Pharmaceuticals d.d. Process for the isolation and / or purification of proteins
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US20060263368A1 (en) * 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US11103592B2 (en) 2016-11-09 2021-08-31 Philogen S.P.A. IL2 and TNF mutant immunoconjugates
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851626B (no) * 1984-07-05 1985-11-26 Genentech Inc
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
JPS63291590A (ja) * 1987-05-25 1988-11-29 Teijin Ltd 新規生理活性ポリペプチド
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide

Also Published As

Publication number Publication date
IL100062A0 (en) 1992-08-18
CA2055168A1 (en) 1992-05-22
UY23327A1 (es) 1992-05-19
US5422104A (en) 1995-06-06
EP0486908A3 (en) 1992-11-19
ZA919035B (en) 1992-08-26
NZ240595A (en) 1994-09-27
AR245783A1 (es) 1994-02-28
MX9102110A (es) 1992-07-08
HU913595D0 (en) 1992-01-28
FI915379L (fi) 1992-05-22
MC2300A1 (fr) 1993-09-06
PT99560A (pt) 1992-10-30
HUT62034A (en) 1993-03-29
US5652353A (en) 1997-07-29
IE914035A1 (en) 1992-06-03
AU655948B2 (en) 1995-01-19
JPH06256395A (ja) 1994-09-13
FI915379A7 (fi) 1992-05-22
EP0486908A2 (en) 1992-05-27
AU8791591A (en) 1992-05-28
FI915379A0 (fi) 1991-11-14
NO914541D0 (no) 1991-11-20

Similar Documents

Publication Publication Date Title
NO931141L (no) Tnf-muteiner
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
DK209088D0 (da) Medicinpraeparater, deres fremstilling og anvendelse
CA2185352A1 (en) Novel muteins of ifn-.beta.
UY23327A1 (es) Proceso para la preparacion de muteina humana del factor de necrosis tumoral
DK0382019T3 (da) Anvendelse af 5-methyltetrahydrofolsyre, af 5-formyltetrahydrofolsyre og af deres farmaceutisk acceptable salte til fremstilling af farmaceutiske præparater med reguleret frigivelse egnet til anvendelse ved terapi af depressive forstyrrelser, og således fremstillede farmaceutiske præparater
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE236249T1 (de) Tfn-bindende proteine
DK395689A (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
LU90025I2 (fr) Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R)
ATE187493T1 (de) Gp75 als tumorimpfstoff gegen melanome
NO915084L (no) Fremgangsmaate ved fremstilling av human interleukin-5 receptor
SE9402880D0 (sv) New peptide derivatives
DK165975C (da) 3-(substitueret amino)-carbonylderivater af 2,2,5,5-tetramethylpyrrolin eller -pyrrolidin og farmaceutisk acceptable salte deraf, fremgangsmaade til deres fremstilling, antiarrhytmisk farmaceutisk praeparat indeholdende dem og fremgangsmaade til praeparatets fremstilling
WO1988006625A3 (en) Arginine-depleted human tumor necrosis factor
DK0564461T3 (da) Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil
NO881778D0 (no) Inkastiner: nye glykopeptider med enkefalinase-hemmende virkning. fremgangsmaate til deres fremstilling og deres anvendelse som farmasoeytiske preparater.
DK325289D0 (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DK164885A (da) ''humane phenylalaninhydroxylase cdna kloner, humane chromosomale phenylalaninhydroxylasegenkloner og fragmenter deraf, fremgangsmaade til fremstilling deraf og deres anvendelse ved diagnosticering af klassisk phenylketonuri''
ATE103979T1 (de) Menschliches lymphotoxin.